Trials / Terminated
TerminatedNCT02860130
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Vantive Health LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who receive CRRT treatment with no anticoagulation.
Conditions
- Regional Citrate Anticoagulation (RCA)
- Continuous Renal Replacement Therapy (CRRT)
- Acute Kidney Injury
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prismocitrate 18 | Modality of CVVHDF |
| OTHER | No Anticoagulation | Modality of CVVHDF |
Timeline
- Start date
- 2016-09-27
- Primary completion
- 2018-05-12
- Completion
- 2018-05-12
- First posted
- 2016-08-09
- Last updated
- 2025-07-22
- Results posted
- 2021-01-05
Locations
12 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02860130. Inclusion in this directory is not an endorsement.